AC-262 536 60tab/10mg

AC-262 536 60tab/10mg


AC-262 536 60tab/10mg

Developed by Acadia Pharmaceuticals, AC-262  536 was initially created to accelerate the treatment of prostate cancer as well as neurological disorders such as Alzheimer’s disease. The compound is comparable to testosterone in its ability to promote  muscle gain .

Unlike testosterone, the direct binding that occurs between the compound and the body’s androgen receptors allows it to promote muscle growth and strength without increasing the risk of prostate cancer, damage to genital tissues, and elevated liver enzymes.


Add to cart
Buy Now
SKU: 1001 Category:

The benefits of using AC-262 536 are as follows:

1. Clean and stable muscle gain.

2. Reduced risk of prostate cancer by antagonizing the effects of dihydroxytestosterone.

3. The possibility of restoring cognitive abilities in people diagnosed with Alzheimer’s disease.

4. Increased fat loss.

5. Enhanced bone strength.

6. Increase in strength and improvement of aerobic capacity.

7. Does not cause water retention like Ostarine or Andarine.

AC-262 – Product Information

A non-steroidal selective androgen receptor modulator, sometimes referred to as AC262, is AC-262536. AC-262536 has the ability to considerably increase anabolic parameters in these animals, particularly by promoting the development of the levator ani and by reducing high levels of luteinizing hormones, according to a recent chronic research that used castrated male rats over a 2-week program.

IUPAC Name 4-[(1R,3S,5S)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl] AC-262536

CAS Number: 870888-46-3

Molar Mass: 278.355 gmol1 Chemical Formula C18H18N2Onaphthalene-1-carbonitrile

AC-262 History

In order to possibly cure prostate cancer and Alzheimer’s disease, ACADIA Pharmaceuticals first created AC-262 in 2007. Although clinical trials are still pending, animal research have indicated that AC-262 has a potent anabolic effect.

How does AC-262 work?

The testosterone-like action of AC-262. It is more selective in its effect, though, and does not bind to androgen receptors. The prostate gland is mostly spared by AC-262 since it primarily targets bone and muscle androgen receptors. In essence, it is being investigated for its ability to bind to androgen receptors in the body, but exclusively in skeletal muscles.

The results above were confirmed by a 2-week chronic investigation in castrated male rats.

When androgens have negative effects, the prostate and seminal vesicles frequently grow significantly in size in castrated rats. According to the study, testosterone caused the size of the prostate to expand by ten times, but AC-262 had negligible effects.

In comparison to castrated rats given with vehicle, those treated with testosterone had seminal vesicles that were 14 times larger. The 3mg/kg dosage of AC-265236 had only a minimal impact, nevertheless. Only 29.92.2% more seminal vesicles than with TP therapy were seen at the maximum dosage.

While achieving 117% and 66% of the highest effects found with testosterone, respectively, AC-265236 had a favorable influence on endocrine and anabolic markers. Therefore, AC-265236 exhibits good tissue-selectivity characteristics with no risk of deleterious androgenic effects.

Research on AC-262

The effects of AC-262 on animals have been widely examined, however, there are no studies on its effects on people. The latter have demonstrated that this SARM had a variety of effects on research participants, including accelerated muscle development and decreased LH levels, among others.

Muscle Mass and AC-262

Strong anabolic effects of AC-262 on muscle mass were shown in a 2-week investigation in castrated male rats. It brought back the weight of the levator ani to around 70% of its peak impact when combined with T. Additionally, compared to T, AC-262’s maximal effects in these tissues were substantially less pronounced.

Both muscle development and endocrinological results were significantly influenced by AC-265236’s anabolic actions. Because of its advantageous anabolic effects, AC-265236 constitutes a new family of selective androgen receptor modulators (SARMs).

AC-262 and Luteinizing Hormone

The pituitary gland in your body secretes luteinizing hormone. It is essential for the growth of sexuality in both men and women. However, if LH levels are greater than average, a variety of issues might arise, such as infertility in women, low sex drive in men, and early or delayed puberty in kids.

In the previously described two-week research, AC-262 reduced plasma LH increases brought on by castration. AC-265236 substantially reduced LH levels by 40% at the dosage of 3 mg/kg. The effects of AC-265236 on LH suppression were substantially more pronounced than T at the dosages of 10 and 30mg/kg.

Alzheimer’s disease and the compound AC-262

In a rat trial, the drug AC-265236 demonstrated treatment potential for Alzheimer’s disease and age-related cognitive decline. In the brain after castration, this SARM increased levels of androgen receptors. Additionally, it counteracted female mouse mice’s lower recall of spatial information.

These results show that SARMs, like testosterone and DHT, counteract cognitive abnormalities in apoE4 female mice at 6 months of age.

FAQs about AC-262

Is AC-262 legal?

As a research chemical, AC-262 is acceptable for purchase and sale. Because of its categorization, this substance may only be used for research and scientific reasons. Due to the absence of human research, we are unable to employ AC-262 since we are unaware of the hazards.

Is AC-262 Fat Loss Inducing?

No mention of fat loss has been made in any of the studies on AC-262 that have been done to yet. Therefore, more research is required to confirm or disprove this claim.

Do SARMs Improve Endurance and Performance Levels?

SARMs are performance boosters, according to research. In test participants, they promote anabolism (i.e., increase muscle growth and strength) and speed up the recuperation process following exercise.


An innovative SARM called AC-262 shows selectivity for bone and muscle tissue but not for reproductive tissues. Additionally, this SARM may stimulate greater spatial memory in animal test participants and boost muscular development. The long-term effects of AC-262 remain unknown due to the lack of randomized, large-scale clinical research.


Medical advice is not provided by this information, which is purely for educational reasons. ONLY LABORATORY AND RESEARCH USES ARE PERMITTED FOR THE PRODUCTS DESCRIBED HEREIN. The proper Institutional Review Board (IRB) must supervise all clinical research projects. According to the requirements of the Animal Welfare Act (AWA), all preclinical research must be carried out under the direction of the relevant Institutional Animal Care and Use Committee (IACUC).

Only informative objectives are permitted and required for the usage of our content. Before making any purchase based on your own particular circumstances, it is crucial to conduct your own analysis and research from Reliable Sources. Any information you see on our website and want to rely on should be independently checked and verified.

Please note that none of our products are intended for veterinary or human use but only for LABORATORY AND RESEARCH PURPOSES.

Product intended for research purposes

Additional information:

  • The product (substance) isn’t a food or diet supplement and is unsuitable for human consumption.
  • Keep out of children’s reach.
  • Keep the container tightly closed.
  • Store in a dry, cool and shaded place; protect from moisture.
  • Store only in the original container.
  • Avoid contact during pregnancy and breastfeeding.
  • Consult a doctor if feeling unwell or having adverse effects related to contact with the substance.

The substance is not a food product or dietary supplement, it is not suitable for human consumption. The product is classified as a chemical reagent approved for trading in the European Union, it can only be used for scientific research.


There are no reviews yet.

Be the first to review “AC-262 536 60tab/10mg”

Your email address will not be published. Required fields are marked *